Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. It is grouped under the following drug class(es): Hypoglycemics and Sulfonylureas. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Glucotrol, Glydiazinamide and Melizide. Its PubChem CID is 3478.
Glipizide
| CAS No | 29094-61-9 |
|---|---|
| Molecular Formula | C21H27N5O4S |
| Molecular Weight | 445.5 g/mol |
| Synonyms | N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus.
The listed CAS number is 29094-61-9.
The listed molecular formula is C21H27N5O4S.
The listed molecular weight is 445.5 g/mol.
N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide.
The source lists Glucotrol, Glydiazinamide and Melizide.